An observational study in Laryngeal Neoplasms, Squamous Cell Carcinoma of the Larynx and Pharyngocutaneous Fistula, sponsored by IRCCS San Raffaele. Recruiting at 26 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.
PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.
This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).
Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.
The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.
257 studies on the registry are indexed under Laryngeal Neoplasms; 68 are open to participants now.
This study's planned enrollment of 950 is above the median of 100 across 60 observational studies indexed under Laryngeal Neoplasms.
Browse Laryngeal Neoplasms studies →IRCCS San Raffaele is the lead sponsor of 456 studies on the registry; 236 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.
Other: Compressive neck dressing
Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.
Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.
Incidence of pharyngocutaneous fistula
Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).
Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days
Incidence of pharyngocutaneous fistula by duration of compressive dressing
Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).
Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to onset of pharyngocutaneous fistula
Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.
Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days
Type of management of pharyngocutaneous fistula
Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.
Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days
Resolution of pharyngocutaneous fistula
Number and percentage of patients whose fistula resolved, by initial group and type of management.
Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to resolution of pharyngocutaneous fistula
Number of days from diagnosis to resolution of the fistula, by initial group and type of management.
Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days
Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.
Time frame: After publication of the study results in a peer-reviewed journal.
Access criteria: Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).
Started May 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.